Overview of the Acquisition
Datavant, a company specializing in data sharing technology, has announced its acquisition of Aetion, a firm dedicated to real-world evidence (RWE) in healthcare. This merger aims to create a comprehensive RWE platform that will assist healthcare and life sciences organizations in addressing research inquiries regarding the clinical effectiveness of both developing and existing therapies.
Key Features of the New Platform
- The combined platform will facilitate the movement of healthcare records across more than 70,000 hospitals and clinics.
- Aetion’s RWE solutions cater to a variety of stakeholders, including biopharmaceutical companies, medical device manufacturers, payers, and regulatory bodies.
- The collaboration will enhance capabilities in data discovery, linkage, privacy, curation, and advanced analysis.
- Healthcare partners will benefit from analytics-driven insights, improving decision-making processes.
Recent Developments
This announcement follows the launch of Datavant Connect, which utilizes AWS Clean Rooms to streamline data discovery and evaluation, thereby accelerating insights. The integration of Aetion is expected to:
- Enhance data discovery features within the Datavant Connect platform.
- Strengthen privacy assessments.
- Provide customers with access to clean datasets and analytics.
Statements from Leadership
Arnaub Chatterjee, president and general manager of life sciences at Datavant, emphasized the importance of this acquisition, stating, “By merging Datavant’s and Aetion’s capabilities, we will be positioned to deliver innovative tools for data feasibility and assessment, ultimately enabling equitable access to data.”
Broader Industry Context
This acquisition aligns with Datavant’s ongoing efforts to expand its partnerships within the pharmaceutical sector. Recently, Datavant extended its collaboration with Boehringer Ingelheim to enhance RWE initiatives across numerous clinical trials.
In addition, Datavant has previously partnered with Socially Determined to provide life sciences companies with insights into social risk factors, aiming to improve health equity and patient outcomes.
Future Prospects
With the acquisition of Aetion, Datavant is set to enhance its position in the RWE market, providing a more robust platform for healthcare data analysis and decision-making. This move is expected to foster greater integration of real-world data into drug development processes, ultimately benefiting patient care.